FDA withdraws Meridia for increased Heart and Stroke Risk

Meridia (sibutramine): FDA Mandates Withdrawal Due to Risk of Serious Cardiovascular Events including heart attack and increased risk of stroke Source: fda.gov AUDIENCE: Primary Care, Consumers ISSUE: Abbott Laboratories and FDA notified healthcare professionals and patients about the voluntary withdraw of Meridia (sibutramine), an obesity drug, from the U.S. market because of clinical trial data […]